Nanobiotix Files August 2025 6-K Report

Ticker: NBTX · Form: 6-K · Filed: Aug 27, 2025 · CIK: 1760854

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, routine-filing

Related Tickers: NBTX

TL;DR

Nanobiotix (NBTX) filed its monthly 6-K for August 2025, standard procedure for foreign issuers.

AI Summary

Nanobiotix S.A. filed a Form 6-K on August 27, 2025, reporting its activities for the month of August 2025. The company, a foreign private issuer, is based in Paris, France, and operates in the pharmaceutical preparations sector. This filing is made under the Securities Exchange Act of 1934 and indicates the company files annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and stakeholders regarding Nanobiotix S.A.'s ongoing operations and compliance as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer activities and does not contain significant new financial or strategic information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What is Nanobiotix S.A.'s primary business sector?

Nanobiotix S.A. is classified under the Pharmaceutical Preparations sector (SIC code 2834).

Which form does Nanobiotix S.A. use for its annual reports?

Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F.

Where is Nanobiotix S.A. headquartered?

Nanobiotix S.A.'s principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.

What is the filing date of this specific Form 6-K?

This Form 6-K was filed on August 27, 2025.

Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2025-08-27 12:38:58

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: August 27, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing